<DOC>
	<DOCNO>NCT00866190</DOCNO>
	<brief_summary>The purpose study determine : safe take SQ109 ( experimental tuberculosis treatment ) day mouth 2 week 2 different dosage ; well body accepts ; SQ109 enter leave body blood tissue time ; amount detect blood ; long stay body . The study involve 30 volunteer : 24 receive SQ109 6 receive placebo ( inactive substance ) . Qualified participant admit study unit within 28 day screen stay inpatient approximately 2 week . During period receive study drug complete schedule procedure include multiple blood draw . After discharge , 14 day follow period . Total study participation 56 day .</brief_summary>
	<brief_title>Dose Escalation Study SQ109 Healthy Adult Volunteers</brief_title>
	<detailed_description>Tuberculosis ( TB ) one important global health problem . According recent estimate World Health Organization , 8 million new case TB 1.9 million death TB occur annually , make TB second lead cause death infectious pathogen . Due multidrug resistant TB , need new effective drug treat TB well recognize . This study phase 1B , prospective , single-center , double-blinded , randomize , placebo-controlled , clinical study SQ109 evaluate single-daily dose tolerability pharmacokinetics ( PK ) oral SQ109 healthy subject . The objective study : determine safety tolerability SQ109 administer daily 14 day healthy male female volunteer ; ass single dose multiple dose PK SQ109 administer daily 14 day healthy male female volunteer ; ass single dose multiple dose PK SQ109 administer twice per week 5-day loading regimen healthy , male female volunteer . A total 30 subject , age 18-45 , enrol study , allocate equally among 3 cohort 10 subject , 8 treat active drug 2 placebo . Subjects Cohorts 1 3 receive oral dose 75 mg 150 mg , respectively , study medication daily 14 day . Subjects Cohort 2 receive 150 mg daily 5 day follow 2 additional dos 150 mg Days 9 14 . Subject participation include screen visit within 28 day study entry , 14 day in-patient treatment period , 14 day out-patient follow-up phase . Safety assess study personnel continually 14 day in-patient treatment period out-patient follow-up phase . Adverse event record subject . Other safety measure include laboratory test , electrocardiogram ( ECGs ) , visual neurological assessment , physical examination , vital sign . Study duration approximately 6 month . Subject participation duration 56 day .</detailed_description>
	<criteria>Subject must 18 45 year age ( inclusive ) . Subject must healthy male female volunteer ( i.e. , hematology , clinical chemistry urinalysis test must within studydefined range . Clinical test must perform within 28 day receive first dose study drug . Body Mass Index ( BMI ) must 18.0 30.0 kg/m^2 inclusive . Subject must Tuberculin Skin Test/Purified Protein Derivative ( TST/PPD ) negative ( within previous 1 year ) Screening . The TST/PPD may omit subject present write evidence negative test previous 12 month . Subject must able give voluntary write informed consent study related procedure perform . If female , childbearing potential agrees avoid become pregnant day screen entire participation trial ( Day 28 ) use one follow acceptable method birth control plus recommend use barrier method ( condom ) male partner ( even vasectomize ) : 1. intrauterine contraceptive device 2. diaphragm combination contraceptive jelly , cream , foam 3. spermicide 4. abstinence Nonchildbearing potential define postmenopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy status hysterectomy . Hormonal contraceptives type form ( include oral , transdermal , vaginal depot preparation ) allow study . All female subject childbearing potential must negative serum pregnancy test screening within 24 hour first dose study product . Male subject must agree use acceptable barrier method birth control ( abstinence use condom spermicide ) screening Study Day 28 advise recommend use additional birth control female sex partner throughout study . Subject agree donate blood study 30 day Study Day 28 . Subject agree comply study requirement , include clinic house rule . A history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , opinion Principal Investigator ( PI ) , would jeopardize safety subject impact validity study result . Subject abnormal diet 4 week precede study . Abnormal diet define diet subject significant change eat habit ( e.g. , liquid diet ) unbalance diet ( e.g. , protein , high fat , low carbohydrate , etc. ) . Subject receive investigational drug clinical trial within 30 day prior study initiation . Subject use overthecounter ( OTC ) medication , include vitamin herbal supplement , within 7 day prior Day 1 study , unless opinion PI , substance would likely impact conduct study , include pharmacokinetics ( PK ) SQ109 . Subject use prescription medication within 14 day prior Day 1 study , use hormonal preparation contain sex hormone within 30 day prior Day 1 study . Subject current medical condition require treatment medication , either prescription OTC . Subject treat know CYP450 enzyme alter drug azoles , antifungal , barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior Day 1 study . Subject positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody and/or positive urine screen alcohol drug abuse . Subject baseline QTc interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) family history prolong QTc syndrome premature cardiac death . Subject Wolf Parkinson White Syndrome ( WPW ) family history WPW history supraventricular tachycardia syncope . Subject live person active tuberculosis ( TB ) past 12 month travel area endemic TB within past 12 month . Subject abnormal result Ishihara color test , funduscopic exam , current optic neuritis know retinal disease . Subject uncontrolled intercurrent illness ( i.e. , active infection ) fever ( oral temperature great equal 100.0 degree Fahrenheit great equal 37.7 degree Celsius ) . Subject major surgery within 4 week study entry . Women pregnant breastfeeding . Subject donate blood within past 30 day prior Day 1 study . Subject allergy ethambutol relate compound . Subject employee family member employee Sequella , Quintiles , DynPort Vaccine Company LLC ( DVC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Mycobacterium tuberculosis , SQ109</keyword>
</DOC>